The identified immune-related predictive signature, including CD70, TNFRSF9, EGFR, PDGFD and S100A6, will facilitate the development of personalized therapy for osteosarcoma and provide new insights into the role of the tumor immune microenvironment in regulating patients’ responses to chemotherapy. Here, S100A6 is linked to neoplasm.